The U.S. Food and Drug Administration (FDA) has approved it to improve wakefulness in adults with EDS associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD).

Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...

People who live with narcolepsy — about ... GHB and criminally used as a date rape drug — has been sold under the brand name Xyrem after gaining FDA approval in 2002. In order to bring it ...

The FDA approved the oral medication July 29 ... Wakix (pitolisant) for pediatric narcolepsy: Originally approved in 2019 for adults, the non-controlled substance's June 24 approval extended ...

Lumryz (sodium oxybate) is a brand-name oral liquid prescribed for narcolepsy in adults and ... Note: After the FDA approves a drug, it tracks and reviews side effects of the medication.

Shares in Axsome Therapeutics have rocketed on FDA ... approved in March 2019 and is administered as a nasal spray twice a week for four weeks. However, it has a broader label as unlike J&J's drug ...

About LUMRYZ™ (sodium oxybate) for extended-release oral suspension LUMRYZ is an extended-release sodium oxybate medication approved by the FDA on May 1, 2023, as the first and only once-at-bedtime ...